Recently, Hangzhou Disern Medical Biotechnology Co., Ltd. has proudly declared the successful closure of its Series A2 funding round, amassing tens of millions of yuan. This significant financing endeavor was spearheaded by Fortune Capital, with substantial contributions also coming from Panlin Capital. WinX Capital played a pivotal role as the exclusive financial advisor in this transaction. The funds raised will be strategically allocated to expedite the market adoption of Disern Medical's ultra-microsurgery robots.

Disern Medical is at the forefront of the ultra-microsurgery robot sector, prioritizing clinical requirements as its guiding principle. By harnessing robot-assisted technology, the company achieves operations with micron-level precision. Its groundbreaking ophthalmic surgery robot has already gained entry into the 'green channel' for expedited review of innovative medical devices by the National Medical Products Administration. This advancement is poised to significantly enhance the stability and precision of retinal surgeries, offering a beacon of hope to patients afflicted with eye diseases.

Moreover, in the realm of general microsurgery, Disern Medical's robot stands as a valuable ally to surgeons, enabling them to perform surgeries of exceptional quality. This, in turn, elevates success rates and enhances the overall quality of life for patients. Presently, Disern Medical boasts a diverse product lineup, encompassing ophthalmic and microsurgical surgery robots. The company is relentlessly driving product innovation and iterations while concurrently pursuing a robust globalization strategy.